Loibner 2017

Hans Loibner, Chief Executive Officer,
Executive Management

PhD in Organic Chemistry from the University of Vienna. More than 20 years in R&D management at Sandoz/Novartis and for 18 years acting as CEO of Biotech companies ; since 1985 engaged in clinically oriented cancer immunotherapy. Main responsibilities: Executive Management.

> contact

 

pld 180119gr_1

Peter Llewellyn-Davies, Chief Financial Officer,
Executive Management

CFO/CBO with an over 25 year track record in financing activities, international M&A deals, company turnarounds, licensing transactions, in particular in healthcare industries including Wilex and Medigene (Link to CV). Main responsibilities: Finance, Business Development, Corporate Communications, Legal Affairs

> contact

 

Mutschlechner2017

Oliver Mutschlechner, Chief Development Officer,
Extended Management Board

PhD in Biochemistry/Biotechnology (Technical University Vienna). Over 20 years of experience in development of biologicals in R&D, pharma and biotech (Octapharma, Intercell, Apeiron). Positions in R&D, QC/QA, qualified person, regulatory affairs and management. Strong background in generating value by successful transition from early development to global commercialization.

> contact